269 related articles for article (PubMed ID: 23232571)
1. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.
Maeda D; Shih IeM
Adv Anat Pathol; 2013 Jan; 20(1):45-52. PubMed ID: 23232571
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
3. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
4. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
6. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
7. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
8. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
9. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
10. Seromucinous Tumors of the Ovary. What's in a Name?
Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2016 Jan; 35(1):78-81. PubMed ID: 26598986
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
12. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
13. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
[TBL] [Abstract][Full Text] [Related]
14. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
15. [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].
Staebler A
Pathologe; 2011 Nov; 32 Suppl 2():265-70. PubMed ID: 21809064
[TBL] [Abstract][Full Text] [Related]
16. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer.
Siufi Neto J; Kho RM; Siufi DF; Baracat EC; Anderson KS; Abrão MS
J Minim Invasive Gynecol; 2014; 21(1):55-63. PubMed ID: 23962574
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
18. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
[TBL] [Abstract][Full Text] [Related]
20. Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Sanuki K; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Oncotarget; 2018 Mar; 9(19):14754-14763. PubMed ID: 29599905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
